<DOC>
	<DOCNO>NCT00008697</DOCNO>
	<brief_summary>The purpose study evaluate efficacy toxicity infusional arsenic trioxide treatment patient relapse refractory acute promyelocytic leukemia ( APML ) . In addition , correlation pharmacokinetic data therapeutic response therapy-related toxicity seek .</brief_summary>
	<brief_title>Arsenic Trioxide Treating Patients With Refractory Recurrent Acute Promyelocytic Leukemia</brief_title>
	<detailed_description>OUTLINE : This dose-escalation study . Patients receive arsenic trioxide IV 2 hour daily 28 day follow 14 day rest period . Patients may receive 3 course treatment . Dose escalation continue cohort 3-6 patient maximum tolerate dose ( MTD ) minimum effective dose ( MED ) determine . The MTD define dose precede 2 patient experience dose limit toxicity . The MED define dose 4 6 patient achieve complete cytogenetic molecular response . After MTD MED determine , additional 20 patient enrol dose level . Patients follow monthly 6 month every three month additional 1.5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>INCLUSION CRITERIA 1 . APML diagnosis base upon morphological , histochemical , and/or flow cytometric criterion , confirm upon review central , studydesignated hematologic pathologist ; OR relapse acute leukemia bearing ( 15:17 ) translocation variant APML translocation involve retinoic acid receptor alpha gene chromosome 15q22 , base cytogenetics PCR . 2. disease first subsequent relapse , follow standard induction consolidation chemotherapy ( alltrans retinoic acid ) and/or allogeneic bone marrow/stem cell transplantation ; OR failure achieve initial complete remission ATRA standard chemotherapy . EXCLUSION CRITERIA 1 . Availability fully HLAmatched sibling donor patient otherwise felt candidate allogeneic bone marrow/stem cell transplantation ; patient partially HLAmatched sibling match unrelated donor remain eligible study entry . 2. pregnancy . 3 . Patients significantly impaired leave ventricular ejection fraction ( &lt; 40 % ) ineligible study . Patients renal failure creatinine clearance le 25 ml/min require hemodialysis ineligible study . Otherwise , rigid exclusion criterion base upon age , performance status , comorbidity . Decisions regard enrollment patient factor may relevant individualized left discretion investigator . Central venous access require patient . Patients childbearing potential must agree use contraception sexual intercourse undergo treatment arsenic trioxide .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>adult acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>childhood acute promyelocytic leukemia ( M3 )</keyword>
</DOC>